As shared on GlobeNewswire, a biotechnology company called ABLi Therapeutics has released encouraging findings from a research study on a potential new Parkinson’s treatment called risvodetinib. Here’s what you need to know in straightforward terms.

What They Studied

Researchers analyzed blood and spinal fluid samples from up to 80 people with early-stage, untreated Parkinson’s disease. They measured 11 different biological markers — think of these as health signals in the body that show what’s happening at the cellular level. The goal was to see if a daily medication could improve these warning signs.

What They Measured

Biomarkers are measurable signs in your body that indicate health or disease. In this study, they tracked:

• Alpha-synuclein buildup — a sticky protein that damages brain cells in Parkinson’s (the main culprit behind the disease)
• Brain inflammation — when the brain’s immune system overreacts, causing damage
• Cell damage and energy problems — signs of dying nerve cells

What They Found

After 12 weeks of daily treatment with risvodetinib, the researchers saw improvements across all these markers:

• The medication successfully blocked the target protein (c-Abl kinase — a cellular messenger that, when overactive, contributes to Parkinson’s)
• Harmful alpha-synuclein proteins significantly decreased, especially at higher doses
• Brain inflammation was substantially reduced below starting levels
• These improvements happened at all three dose levels tested (50 mg, 100 mg, and 200 mg daily)

Why This Matters

Most current Parkinson’s medications only manage symptoms like tremors and stiffness — they don’t slow the disease’s progression. This research suggests risvodetinib may actually modify the disease itself, potentially slowing or reversing damage rather than just treating symptoms.

Next Steps

ABLi plans to use these findings in upcoming larger clinical trials and in discussions with the FDA (Food and Drug Administration) to advance the drug toward potential approval.

While this treatment shows promise in early testing, it’s important to remember that more research in larger patient groups is needed before any new medication becomes available to patients.